{ "ProductData": { "ID": "RTD000909", "ProductType": "Others", "BrandName": "FITC anti-C1q Primary Antibody", "ProductNameAddition": "", "RegulatoryDisclaimer1": "For in vitro diagnostic use.", "DisclaimerGroup1": "IVD", "RegulatoryDisclaimer2": null, "DisclaimerGroup2": null, "RegulatoryDisclaimer3": null, "SampleType": [ "Frozen tissue" ], "LicenseDisclaimers": [ ], "RelatedLinks": "", "Clone": "", "ControlTissue": [ "Frozen, Diseased Skin or Diseased Renal Tissue" ], "ISOtypes": "", "Species": [ "Goat" ], "StainLocalization": [ "" ], "ProductNameGlobal": "C1q Primary Antibody FITC" }, "ProductImageDetails": { "ImagePath": "https://pim-media.roche.com/Images/Product_RTD000909_im_en.jpg", "ImageType": "Image main" }, "Product2Taxonomy": { "Product2TaxonomyReferences": [ { "StructureSystemIdentifier": "Product_Grouping", "StructureSystemName": "Product Grouping", "NodeID": "05-0002", "StructureNodeStatus": "Active", "NodeName": "IHC Primary Antibodies" }, { "StructureSystemIdentifier": "OWP_Techniques", "StructureSystemName": "Techniques", "NodeID": "073-00", "StructureNodeStatus": "Active", "NodeName": "Immunohistochemistry (IHC)" }, { "StructureSystemIdentifier": "Lab_Type", "StructureSystemName": "Lab Types", "NodeID": "080-00", "StructureNodeStatus": "Active", "NodeName": "Pathology Lab" }, { "StructureSystemIdentifier": "Disease_Areas", "StructureSystemName": "Disease Areas", "NodeID": "38-00-00", "StructureNodeStatus": "Active", "NodeName": "Skin cancer" }, { "StructureSystemIdentifier": "Product_Solutions", "StructureSystemName": "Product Solutions", "NodeID": "010", "StructureNodeStatus": "Active", "NodeName": "Histopathology" }, { "StructureSystemIdentifier": "Applications", "StructureSystemName": "Applications", "NodeID": "99-00-00", "StructureNodeStatus": "Inactive", "NodeName": "" }, { "StructureSystemIdentifier": "Pathogens", "StructureSystemName": "Pathogens", "NodeID": "99-00-00", "StructureNodeStatus": "Inactive", "NodeName": "" }, { "StructureSystemIdentifier": "Health_Topics", "StructureSystemName": "Health Topics", "NodeID": "22-00-00", "StructureNodeStatus": "Active", "NodeName": "Dermatology" }, { "StructureSystemIdentifier": "OWP_Product_Types", "StructureSystemName": "Product Types", "NodeID": "15-000-00", "StructureNodeStatus": "Active", "NodeName": "Primary Antibody" }, { "StructureSystemIdentifier": "OWP_Family", "StructureSystemName": "Product Families", "NodeID": "080", "StructureNodeStatus": "Active", "NodeName": "BenchMark" } ] }, "Product2Materials": { "P2MaterialReferences": [ { "MaterialNum": "05267994001", "MaterialDescription": "FITC ANTI-C1Q PRIMARY ANTIBODY", "RegisteredProductName": "FITC anti-C1q Primary Antibody", "GTIN": "04015630971473", "ProductCategoryText": "Reagents, kits", "OldMaterialNumber": "760-2688", "PackSizePIM360": "50 tests", "PackSizeDescPIM360": "Not Available", "MaterialAnnotation": "", "ReadyForUse": "true", "OrderInformation": "" } ] }, "Product2Products": { "Product2ProductReference": [ { "ProductID": "INS_2099", "BrandName": "BenchMark ULTRA", "ProductNameAddition": "", "ReferenceType": "Instrument", "Classification": [ { "IdentifierofStructureSystem": "1", "NameofStructureSystem": "GPCH", "StructureNodeID": "2300", "StructureGroupPath": "Histology->Systems / Digital Products->Advanced Staining->BenchMark ULTRA", "StructureGroupName": "BenchMark ULTRA", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "OWP_Product_Types", "NameofStructureSystem": "Product Types", "StructureNodeID": "10-000-00", "StructureGroupPath": "Analyzer Instruments and Systems", "StructureGroupName": "Analyzer Instruments and Systems", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "OWP_Family", "NameofStructureSystem": "Product Families", "StructureNodeID": "080", "StructureGroupPath": "BenchMark", "StructureGroupName": "BenchMark", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Lab_Type", "NameofStructureSystem": "Lab Types", "StructureNodeID": "080-00", "StructureGroupPath": "Pathology Lab", "StructureGroupName": "Pathology Lab", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Product_Solutions", "NameofStructureSystem": "Product Solutions", "StructureNodeID": "010", "StructureGroupPath": "Histopathology", "StructureGroupName": "Histopathology", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "OWP_Techniques", "NameofStructureSystem": "Techniques", "StructureNodeID": "073-00", "StructureGroupPath": "Immunohistochemistry (IHC)", "StructureGroupName": "Immunohistochemistry (IHC)", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "OWP_Techniques", "NameofStructureSystem": "Techniques", "StructureNodeID": "075-00", "StructureGroupPath": "In situ Hybridization (ISH)", "StructureGroupName": "In situ Hybridization (ISH)", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Applications", "NameofStructureSystem": "Applications", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "Disease_Areas", "NameofStructureSystem": "Disease Areas", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "Pathogens", "NameofStructureSystem": "Pathogens", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "Health_Topics", "NameofStructureSystem": "Health Topics", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" } ] } ] }, "ProductSpec": [ { "ProductSpecVariant": { "Chapters": [ { "Name": "Storage Conditions (Product)", "Value": "Store at 2-8°C. Do not freeze.", "Language": "en", "Country": "XG", "Code": "Storage Conditions (Product)" }, { "Name": "Intended Use", "Value": "Cet anticorps est conçu pour être utilisé en diagnostic in vitro (DIV).

L’anticorps FITC anti-C1q (complément 1q) Primary Antibody de Ventana Medical Systems (Ventana) est un anticorps polyclonal de chèvre marqué à la fluorescéine et dirigé spécifiquement contre les C1q humains. Ce réactif doit être utilisé en association avec une gamme d’anticorps afin de faciliter l’identification du complément 1q dans les tissus cibles des C1q (par exemple, pour le diagnostic des maladies rénales ou cutanées). L’anticorps FITC anti-C1q est destiné à être utilisé en laboratoire pour la coloration qualitative des coupes de tissu congelé sur un Ventana Automated Slide Stainer.

L'interprétation clinique de toute coloration ou absence de coloration doit être complétée par des études morphologiques et l'analyse de contrôles adéquats. L'évaluation doit être accomplie par un pathologiste qualifié et tenir compte de l'historique clinique du patient et d'autres tests diagnostiques.", "Language": "fr", "Country": "XG", "Code": "Intended Use" }, { "Name": "Content", "Value": "FITC anti-C1q contains sufficient reagent for 50 tests.

One 5 mL dispenser of FITC anti-C1q; contains approximately 333 µg (66.6 µg/mL) of a goat polyclonal antibody directed against human C1q. The antibody is diluted in a Tris based buffer containing carrier protein and preservative.
Total protein concentration of the reagent is approximately 0.5 µg/mL.", "Language": "en", "Country": "XG", "Code": "Content" }, { "Name": "Background Information", "Value": "Fluorescent antibodies have been used to detect specific antigens in cells or tissue for over 40 years.¹ An informative overview of the use of FITC-conjugated antibodies as effective and specific immunofluorescent markers for cellular antigens may be found in Faulk and Hijmans.² Use of the immunofluorescence technique has resulted in an increased overall understanding of renal,³ and dermal⁴ pathologies.
FITC anti-C1q contains a goat polyclonal antibody raised against purified human C1q. The antibody is obtained through gel filtration purification of the goat gamma globulin fraction, followed by reaction with fluorescein isothiocyanate to produce a fluorescein to protein ratio of 3 to 6 mol/mol. The excess dye is then removed by dialysis and the conjugated globulin is further fractionated on DEAE cellulose to remove over and under labeled protein.⁵ Immunofluorescent detection of C1q in human tissues has been described elsewhere.⁶
Anti-C1q binds specifically with human complement 1q and does not react with other complement components or serum proteins.


1. Coons AH, Melvin H. Localization of Antigen in Tissue Cells. (II). Improvements in a Method for Detection of Antigen by Means of Flourescent Antibody. Albert & Kaplan. 1-13, 1950.
2. Faulk WP, Hijmans W. Recent developments in immunofluorescence. Prog Allergy.16:9-39, 1972.
3. McCluskey RT. The value of immunofluorescence in the study of human renal disease. J Exp Med. Sep 1;134(3):Suppl:242s+, 1971.
4. Wick MR, Ritter JH, Humphrey PA, Swanson PE. Immunopathology of nonneoplastic skin disease: a brief review. Am J Clin Pathol. Apr;105(4):417-29, 1996.
5. Wood BT, Thompson SH, Goldstein G. Fluorescent antibody staining. 3. Preparation of fluorescein-isothiocyanate-labeled antibodies. J Immunol. Aug;95(2):225-9, 1965.
6. Loos M, Storz R, Muller W, Lemmel EM. Immunofluorescence studies on the subcomponents of the first component of complement (C1): detection of C1q and C1s in different cells of biopsy material and on human as well as on guinea pig peritoneal macrophages. Immunobiology.158(3):213-24, 1981.", "Language": "en", "Country": "XG", "Code": "Background Information" }, { "Name": "Principle", "Value": "FITC anti-C1q may be used as the primary antibody for immunohistochemical staining of frozen tissue sections. In general, immunohistochemical staining allows the visualization of antigens via the sequential application of a specific antibody (primary antibody) to the antigen, a secondary antibody (link antibody) to the primary antibody, an enzyme complex and a chromogenic substrate with interposed washing steps. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. For FITC direct labeled antibodies, the fluorochrome is linked to the primary antibody and therefore no secondary antibody or chromogenic detection step is required. The primary antibody binds specifically to the target antigen and can then be visualized. Results are interpreted using a fluorescent microscope with the appropriate filter set and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.

FITC anti-C1q is optimally diluted for use with Ventana automated slide stainers. Each step in the staining protocol includes incubation for a precise time at a specific temperature. At the end of each incubation step, the sections are rinsed by the Ventana automated slide stainer to stop the reaction and remove unbound material that would hinder the desired reaction in subsequent steps. To minimize evaporation of the aqueous reagents from the specimen-containing slide a coverslip solution is applied in the slide stainer. For more detailed information on instrument operation, refer to the appropriate Ventana automated slide stainer Operator's Manual.", "Language": "en", "Country": "XG", "Code": "Principle" }, { "Name": "Product Purpose", "Value": "Cet anticorps est conçu pour être utilisé en diagnostic in vitro (DIV).

L’anticorps FITC anti-C1q (complément 1q) Primary Antibody de Ventana Medical Systems (Ventana) est un anticorps polyclonal de chèvre marqué à la fluorescéine et dirigé spécifiquement contre les C1q humains. Ce réactif doit être utilisé en association avec une gamme d’anticorps afin de faciliter l’identification du complément 1q dans les tissus cibles des C1q (par exemple, pour le diagnostic des maladies rénales ou cutanées). L’anticorps FITC anti-C1q est destiné à être utilisé en laboratoire pour la coloration qualitative des coupes de tissu congelé sur un Ventana Automated Slide Stainer.

L'interprétation clinique de toute coloration ou absence de coloration doit être complétée par des études morphologiques et l'analyse de contrôles adéquats. L'évaluation doit être accomplie par un pathologiste qualifié et tenir compte de l'historique clinique du patient et d'autres tests diagnostiques.", "Language": "fr", "Country": "XG", "Code": "Product Purpose" } ] } } ] }